Gensun Biopharma Inc.

Amgen Inc.

Other

Jackie Zeqi Sheng

Bo Liu

Margaret Karow

YuMei Xiong

Kenneth William Walker

Gunasekaran Kannan

Agnes Eva Hamburger

Zhulun Wang

Yi Lin Zhang

Xiaoshan Min

Murielle M Veniant-Ellison

Jie Tang

Grant Shimamoto

Grace Ki Jeong Lee

Wei Zhang

Bryan D Lemon

Tara Arvedson

Barbra Sasu

Xiao-juan Bi

James Rottman

Marissa Mock

Richard Yau

Gregory Dyas

Cherylene Plewa

Huiren Zhao

Yang Li

Thomas Charles Boone

Bei Shan

Thomas J Wolfe

Wen-Chen Yeh

Aaron George Winters

Yi Zhang

Keegan Cooke

Mitsuru Haniu

Khue Truong

Haiqun Jia

Thomas Wolfe

Yumei Xiong

Thomas Gerard Wolfe

Antitumor antagonists that bind specifically to immune checkpoint regulator are disclosed. Also disclosed is a method of treating proliferative disorders with the anti-tumor antagonists.

Bispecific antagonist comprising a LAG-3 binding domain

Checkpoint regulator antagonists that bind specifically to TIGIT, PD-1 and/or PD-L1 are disclosed. Also disclosed are methods of making and using the checkpoint regulator inhibitors, including monospecific, bispecific and trispecific checkpoint regulator antagonists thereof.

Checkpoint regulator antagonists

Provided are trispecific T Cell Engagers or TSMAb's, antibodies that can simultaneously engage three different types of epitopes on the same target or on different targets. More specifically, the invention is directed to trispecific molecules that bind to DLL3, MUC17 or CLDN18.2 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.

Trispecific T cell engagers

Antitumor antagonists that bind specifically to immune checkpoint regulators, angiogenesis pathway regulators and/or TGF pathway regulators are disclosed. Also disclosed are methods for treating proliferative disorders, infections, and immunological disorders with the antitumor antagonists described herein.

Antagonists targeting the TGF-β pathway

Provided are bispecific T Cell Engagers. More specifically, the invention is directed to bispecific molecules that bind to DLL3, MUC17 or CLD18 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.

Bispecific T cell engagers

Antitumor antagonists

Antitumor antagonists that bind specifically to immune checkpoint regulator and/or components of the angiogenesis pathways and/or components of the TGF pathway are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.

Trispecific antagonists

The present invention is directed to an in vitro method of producing a recombinant AAV virion in a mammalian host cell that comprises a functional adenoviral E1A gene (e.g., a HEK 293T cell) and rAAV virions made by the method.

High titer recombinant AAV vector production in adherent and suspension cells

GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Growth differentiation factor 15 (GDF-15) polypeptides

Antitumor antagonists that bind specifically to immune checkpoint regulator are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.

Anti-PD-1 antibodies, antigen-binding portions thereof and checkpoint regulator antogonists comprising the same

The present invention is directed to an in vitro method of producing a recombinant AAV virion in a mammalian host cell that comprises a functional adenoviral E1A gene and rAAV virions made by the method. Host cells are transfected with varying ratios of plasmids comprising the E1A gene and virions.

Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Growth differentiation factor 15 (GDF-15) constructs

Growing community of inventors

Thousand Oaks, CA, United States of America

Jackie Zeqi Sheng